Back to Search
Start Over
Clinical duration of action of different botulinum toxin types in humans
- Source :
- Toxicon : official journal of the International Society on Toxinology. 179
- Publication Year :
- 2019
-
Abstract
- The Botulinum NeuroToxin (BoNT) comprises several serotypes with distinct properties, mechanisms of action, sensitivity and duration of effect in different species. The serotype A (BoNT/A) is the prevalent neurotoxin applied in human's disease. In this paper we present an overview of the current knowledge regarding the duration of effect and the neuromuscular sprouting of different BoNT serotypes in humans. Then, we report the original results of a study in healthy subjects treated with BoNT/A, B, C and F using different neurophysiological techniques. Twelve healthy volunteers (7 men, 5 women) are treated with BoNT/A, B, C and F or placebo in Abductor digiti minimi (ADM) muscle of the hand. Before and after injections, an extensive neurophysiological study is performed with the CMAP amplitude variation, Multi-Motor Unit Action Potentials (MUAPs) analysis, the Turns/Amplitude ratio of interference pattern (IP) and determination of jitter and Fiber Density (FD) at single-fiber electromyography (SFEMG), at week 2 (w2), 4 (w4), 6 (w6) and 8 (w8). A maximal neuromuscular block is obtained at w2 for all the serotypes. Afterwards, the CMAP trend appear similar for BoNT/A, B, and C while, BoNT/F shows a faster recover. Multi-MUAPs analysis and IP detect mild changes at w2 for all serotypes, except for BoNT/F that shows a greater change since w4. SFEMG have minimal changes in FD while, Jitter increase at w2 with a slower decrease over the time for all BoNTs. In conclusion, BoNT/F has earlier sprouting and complete recovery at w8. Other serotypes present a slower and similar profile. The EMG appear useful to study the functional recovery in humans, and these results should provide new evidence for assessing different serotypes. These findings improve our knowledge regarding the methods to evaluate duration of effects and dose equivalents in different serotypes, that in the future could change the clinicians strategy for disease-tailored BoNT therapies.
- Subjects :
- 0106 biological sciences
Botulinum Toxins
Electromyography
Pharmacology
Toxicology
Placebo
01 natural sciences
Injections, Intramuscular
Type A
Injections
03 medical and health sciences
medicine
Neurotoxin
Humans
Botulinum neurotoxins
Botulinum Toxins, Type A
Duration of effect
MUAPs analysis
Intramuscular
0303 health sciences
medicine.diagnostic_test
business.industry
010604 marine biology & hydrobiology
cMAP test
030302 biochemistry & molecular biology
Functional recovery
Botulinum toxin
Amplitude ratio
Botulinum toxins serotypes
EDB test
Fiber density
business
medicine.drug
Subjects
Details
- ISSN :
- 18793150
- Volume :
- 179
- Database :
- OpenAIRE
- Journal :
- Toxicon : official journal of the International Society on Toxinology
- Accession number :
- edsair.doi.dedup.....d7b3b0de6c1422d9886e91b2c48a2966